Roivant Sciences Ltd.

Roivant Sciences Ltd.

Roivant Sciences was launched in 2014 by Vivek Ramaswamy, then a biotech entrepreneur, with a thesis that large pharmaceutical companies routinely deprioritize promising drug candidates. Roivant acquired those assets and housed them in separate subsidiary companies — dubbed 'vants' — each focused on a specific therapeutic area. Notable vants include Axovant (neurology), Dermavant (dermatology), and Cytovant (oncology). Wealth origin traces back to institutional capital from investors including Viking Global Investors and SoftBank Vision Fund (per public filings). Roivant's strategy blends in-house development, external deal-making, and a venture-like spin-out model. The firm targets late-stage clinical assets, often in Phase 2 or 3, where it can de-risk regulatory pathways. It also operates Datavant, a health-data platform that uses AI/ML to structure real-world evidence. Confirmed investments include the spin-out of Dermavant to Organon for up to $1.2B (per Organon, September 2023) and the licensing of brepocitinib from Pfizer (per Pfizer, 2021). Geographic footprint spans North America, Europe, and, via Cytovant, Japan and China. Roivant maintains offices in San Francisco, New York, and London, with an estimated headcount of several hundred across its operating companies. It operates a philanthropic arm, the Roivant Foundation, which is structurally separate. A recent operational event: February 2025 — Roivant announced a strategic partnership with Moderna to develop mRNA-based therapies for rare diseases (per Roivant press release, February 2025). Structural differentiator: Roivant's model of creating multiple independent drug-development companies under a single parent, each with its own management and board, mirrors a multi-family office's portfolio approach. This structure allows Roivant to recycle capital from successful spin-outs back into new vants, avoiding the standard biotech R&D burn-rate trap.